Aarti Pharma Q1 FY24 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
N/A
Capex
Yes
1 of 3 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
Category 3- Company expects revenue growth of 12%-17% over the next few years, reflecting a solid but moderated pace compared to past CAGR of ~18%-20% (Page 12).
- Growth driven by expansion in three segments: Xanthine, API/intermediates, and CDMO/CMO businesses, with the latter poised for faster growth and higher margins (Pages 11-12).
- CDMO/CMO segment anticipated to grow from ~6% contribution currently to potentially 15%+ in 3 years (Page 11).
- Capacity expansions, including debottlenecking and new Atali project (completed by H2 FY25), will enable volume growth and new product commercializations (Pages 6, 11).
- Despite pressure on Xanthine prices, volume increase and capacity expansion aim to maintain or improve absolute EBITDA (Pages 6, 10).
- New product launches, about 40 developments annually, support sales growth alongside broadening customer base in innovator pharma and food/cosmetics (Pages 3, 13).
See what Aarti Pharma management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
- The company has indicated ongoing and upcoming capex projects (e.g., Atali project with INR350-500 crores capex) being funded through existing resources and internal accruals.
- Management highlighted reasonable debt levels and focus on EBITDA and PAT growth but did not specify raising new funds.
- The discussions revolve around optimizing existing capacities, backward integration, and capex funded from internal cash flows.
- No direct references to equity issuance or fresh borrowings for expansion were made during the Q&A or management commentary sections.
See what Aarti Pharma management said on order book — free account, 30 seconds.
Capex plans
Yes- Growth capex of over INR 200 crores incurred in the last couple of years, with INR 130 crores capitalized on the Tarapur project. Ramp-up expected over next 1 to 1.5 years.
- Atali, Gujarat Greenfield project: 80 acres acquired; first phase involves 400k reactor volume capacity, targeting API, intermediates, and CDMO/CMO projects. Completion expected in H2 FY25.
- Additional capacity expansions include debottlenecking Xanthine plant from 4,000 to 5,000 tons per annum, with further debottlenecking planned.
- Maintenance and EHS capex typically INR 50-60 crores per year.
- Future capex plans include potential for 2-3 additional blocks at current API sites based on demand, with flexibility to scale as utilization improves.
- Capital employed for backward integration to reduce imports and improve margins, especially to reduce dependence on China.
Track Aarti Pharma — get its next earnings analysis in your feed
Margin guidance
Category 3- Management expects EBITDA growth in FY24 to be around 10%-15%, with sustainable EBITDA margins near 20% ±2%.
- Long-term top-line growth guidance is 12%-17% annually, with PAT growth potentially higher due to manageable debt levels.
- The CDMO/CMO segment is anticipated to grow and contribute over 10% to overall business in FY24, driving margin improvement.
- Capacity expansions, including de-bottlenecking xanthine production and the Atali Greenfield project (completion expected H2 FY25), support growth.
- Revenue growth may moderate due to price corrections in segments like Xanthine, but absolute EBITDA and profits are expected to improve through volume increases and operational efficiencies.
- R&D expenditure remains stable, fueling product filings and innovation, which should contribute to longer-term earnings growth.
Order book
- Specific current or expected order book or pending orders details were not explicitly stated in the transcript.
- Management highlighted ongoing growth with projects like Atali (expected completion H2 FY25) aimed at capacity expansion.
- Focus is on increasing tonnage and backward integration to meet demand and maintain margins.
- The CMO/CDMO segment is expected to grow significantly, possibly increasing from 6% to 15% contribution over the next three years.
- The company is actively commercializing new products each year, aiming to file around 40 DMFs per year, with 40 filed to date as of FY23.
- Inventories have increased but management expects these to be sold in upcoming quarters, indicating active order fulfillment underway.
- Overall, the company expects stable or growing EBITDA and is optimistic about future order growth tied to capacity expansion and product pipeline.
How does Aarti Pharma rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureHow does Aarti Pharma rank in Pharmaceuticals & Biotechnology?
Compare Aarti Pharma against every Pharmaceuticals & Biotechnology company (Q1 FY24) on revenue, margins and earnings-call signals.
Continue your research
What Aarti Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- IOL Chemicals (Q1 FY27)
Expansion plans supported by capex of INR 200-250 crores annually, with 60% towards expansion/new products and 40% towards efficiency improvements. Key concall…
- Innova Captab (Q1 FY27)
The company is confident of achieving 20%+ volume growth backed by steady ramp-up in Jammu and existing facilities. Key concall takeaways from Innova Captab…
- Glenmark Pharma. (Q1 FY27)
Chronic respiratory segment in India showing over 25% growth; oncology and cardiovascular segments also strong. Key concall takeaways from Glenmark…
- Strides Pharma (Q1 FY27)
markets continue to be broad-based growth drivers, with 17% YoY growth and expansion in B2B and B2C markets including Europe, UK, Nordics, Africa, LATAM, MENA…